zoonotic; cats are primary reservoirs, and humans and dogs are accidental hosts (1). However, B. claridgeiae was recently detected in rodent fleas in China (9) and B. koehlerae was isolated from feral pigs from the southeastern United States (10), suggesting that these pathogens also have multiple reservoir species.

Clarifying whether Bartonella infections in raccoons are caused by spillover from feral cats needs further study. Additional samples from raccoons and other species in urbanized and undeveloped habitats with different host species composition (e.g., cat-free environment) might enable further Bartonella spp. characterization in wildlife. We suspect urban raccoons and feral cats play a major role in Bartonella spp. transmission.

Acknowledgments

We thank Michael Yabsley, Barbara Shock, Matthew Stuckey, and Bruno Chomel for providing technical advice; and Mark Heth, Jan Rossiter and staff at the Island Animal Hospital, St. Simons Island, Georgia, for assistance with sample collection.

This study was supported by the St. Catherines Island Foundation, Inc., and Odum School of Ecology, University of Georgia, through the course taught by Vanessa Ezenwa and Andrew Park (ECOL/IDIS 8150L).

Jusun Hwang and Nicole L. Gottdenker

Author affiliation: University of Georgia, Athens, Georgia, USA

DOI: http://dx.doi.org/10.3201/eid1907.130100

References

1. Chomel BB, Boulouis HJ, Breitschwerdt EB, Kasten RW, Vayssier-Taussat M, Birtles RJ, et al. Ecological fitness and strategies of adaptation of Bartonella species to their hosts and vectors. Vet Res. 2009;40:29. http://dx.doi.org/10.1051/vetres/2009011

2. Kosoy M, Hayman DT, Chan KS. Bartonella bacteria in nature: where does population variability end and a species start? Infect Genet Evol. 2012;12:894–904. http://dx.doi.org/10.1016/j.meegid.2012.03.005

3. Kosoy MY. Ecological associations between bacteria of the genus Bartonella and mammals. Biological Bulletin. 2010;37:716–24. http://dx.doi.org/10.1134/s1062359010070071

4. Trataris AN, Rossouw J, Amtzen L, Karstaedt A, Frean J. Bartonella spp. in human and animal populations in Gauteng, South Africa, from 2007 to 2009. Onderstepoort J Vet Res. 2012;79:1–8. http://dx.doi.org/10.4102/ojvr.v79i2.452

5. Roux V, Raoul D. The 16S–23S rRNA intergenic spacer region of Bartonella (Rochalimaea) species is longer than usually described in other bacteria. Gene. 1995;156:107–11. http://dx.doi.org/10.1016/0378-1119(94)00919-J

6. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22:4673–80. http://dx.doi.org/10.1093/nar/22.22.4673

7. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011;28:2731–9. http://dx.doi.org/10.1093/molbev/msr121

8. Henn JB, Chomel BB, Boulouis HJ, Kasten RW, Murray WJ, Bar-Gal GK, et al. Bartonella rochaelimae in raccoons, coyotes, and red foxes. Emerg Infect Dis. 2009;15:1984–7. http://dx.doi.org/10.1093/infdis/jip310

9. Li DM, Liu QY, Yu DZ, Zhang JZ, Gong ZD, Song XP. Phylogenetic analysis of Bartonella detected in rodent fleas in Yunnan, China. J Wildl Dis. 2007;43:609–17.

10. Beard AW, Maggi RG, Kennedy-Stoskopf S, Cherry NA, Sandfoss MR, DePerno CS, et al. Bartonella spp. in feral pigs, southeastern United States. Emerg Infect Dis. 2011;17:893–5. http://dx.doi.org/10.3201/eid1705.100141

Address for correspondence: Nicole Gottdenker, Department of Veterinary Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA; email: gottdenk@uga.edu

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the Centers for Disease Control and Prevention or the institutions with which the authors are affiliated.

Rifampin-Resistant Mycobacterium bovis BCG–Induced Disease in HIV-Infected Infant, Vietnam

To the Editor: Guidelines for the diagnosis and management of Mycobacterium bovis BCG disease in HIV-infected children are lacking. BCG strains are intrinsically resistant to pyrazinamide and in some cases have low-level resistance to isoniazid (6). However, data on acquired drug resistance in M. bovis BCG are limited. We describe a case of BCG disease caused by a rifampin-resistant strain of M. bovis BCG in an HIV-infected infant in Vietnam.

The daughter of a known HIV-infected woman, who did not fully adhere to antiretroviral therapy (ART) during pregnancy, received the M. bovis intradermal BCG (Pasteur strain) vaccine at birth. HIV infection was diagnosed in the infant by PCR when she was 8 weeks of age. At 9 months of age, she was admitted to the Pediatric Infectious Diseases Department of the Pham Ngoc Thach Hospital (Ho Chi Minh City, Vietnam) because of a voluminous ipsilateral axillary mass at the site of the vaccination, fever, weight loss, and hepatosplenomegaly. The percentage of CD4+ T cells was 27% (1,620 cells/mm³). Regional BCG disease was clinically diagnosed without microbiological investigation, and a broad antimycobacterial therapy targeting M. tuberculosis complex species was started with 5 mg/kg isoniazid, 10 mg/kg rifampin, and 25 mg/kg pyrazinamide. After 6 weeks of antimycobacterial therapy, ART was initiated with lamivudine, stavudine, and abacavir.

After 6 months of antimycobacterial treatment, the infant was hospitalized again for recurrent inflammation and fistulization of the axillary lymph nodes associated with fever.
Fluid from the axillary mass was collected by fine-needle aspiration for bacteriologic investigations. Direct microscopic examination showed acid-fast bacilli, and the mycobacterial infection was confirmed by culture. By using conventional biochemical methods, the mycobacterial isolate was assigned to the *M. bovis* species. Pyrazinamide was discontinued, and antimycobacterial therapy was continued for 4 supplementary months with rifampin (15 mg/kg) and isoniazid (10 mg/kg). After 2 months, drug susceptibility testing results confirmed pyrazinamide intrinsic resistance and isoniazid and ethambutol susceptibility and showed rifampin resistance. The late inflammatory reaction after introduction of ART was evocative of immune reconstitution inflammatory syndrome. Nevertheless, drug resistance may have contributed. Despite the rifampin resistance, the patient showed clinical improvement, and the rifampin/isoniazid treatment was continued for 2 more months. The child’s BCG disease was cured on completion of 10 months of antituberculous treatment.

Retrospective molecular investigations using the GenoType MTBC Kit (Hain Lifescience, Nehren, Germany) enabled identification of the isolate stored at −80°C as *M. bovis* BCG strain. A mutation in the rpoB gene (codon 531, Ser531Tyr) associated with rifampin resistance was detected by using the GenoType MTBCplus Kit (Hain Lifescience) and partial sequencing of the rpoB gene (5,7). No mutation in the katG and inhA genes, frequently associated with isoniazid resistance, was detected.

To our knowledge, this case is the second report of rifampin-resistant *M. bovis* disease in HIV-infected children. The first report involved a child in South Africa who was vaccinated with the Danish BCG strain (4); this strain shows low-level resistance to isoniazid and therefore has a high risk of evolving to multidrug resistance in instances of suboptimal isoniazid levels. The *M. bovis* BCG Pasteur strain (American Type Culture Collection 35734) used for vaccination in Vietnam is isoniazid and rifampin susceptible and pyrazinamide resistant (9). Despite appropriate antimycobacterial treatment, the relatively low doses of isoniazid (5 mg/kg), poor adherence, or inadequate absorption of drugs because of HIV-related gastrointestinal disease may have resulted in subtherapeutic in vivo drug concentrations and thus in selection of a drug-resistant *M. bovis* BCG strain. This case should alert clinicians of the possible emergence of rifampin-resistant *M. bovis* BCG strains.

Because disseminated BCG disease in HIV-infected children presents a high risk for illness and/or death, these patients should receive optimal tuberculosis treatment (2) based on 4-drug (rifampin, isoniazid, ethambutol, and pyrazinamide) regimen doses for at least 9 months until *M. tuberculosis* is ruled out (3). Untreated local BCG immune reconstitution inflammatory syndrome may not necessarily progress to dissemination; therefore, treatment would not appear necessary (8).

Some studies suggest that the survival of HIV-infected children with BCG disease could be attributed to early initiation of ART in combination with other treatments (1,3). In the South Africa case, the child died, and the authors suggested that this outcome was related to the severity of the clinical features, the severe HIV-related immune suppression, and the absence of ART (4). In the case in Vietnam, despite the emergence of drug resistance, the early initiation of ART in a child with a localized disease, the persistent efficacy of isoniazid, and the spontaneous fistulization of the abscess probably contributed to the good outcome for the infant.

In conclusion, this case highlights the challenges in management of BCG disease in children. It also emphasizes the possible risk for emergence of acquired drug resistance in *M. bovis* BCG strains, complicating the medical management of such cases.

**Acknowledgments**

We are grateful to all the health care teams of Pham Ngoc Thach Hospital for their help in this study. We acknowledge Didier Laureillard for the fruitful discussions.

The Institut National de la Santé et de la Recherche Médicale; Institut de Recherche pour le Développement; Centre National de la Recherche Scientifique; and Pham Ngoc Thach Hospital, particularly the Reference Laboratory for Tuberculosis, provided financial and technical support. This study was developed in the framework of the Centre National de la Recherche Scientifique-Groupements de Recherche International project entitled “Biodiversity and Infectious Diseases in Vietnam.”

**Duc Nguyen Hong,**

**Mai Nguyet Thu Huyen,**

**Nguyen Thi Ngoc Lan,**

**Nguyen Huy Duong,**

**Vi Vi Nguyen Ngo,**

**Duong Tran Ngoc,**

**Khanh Truong Huu,**

**Tuyen Nguyen,**

**Viet Do Chau,**

**Oliver Marcy,**

**Philippe Van de Perre,**

**Anne-Laure Bañuls,**

**and Sylvain Godreuil**

Author affiliations: Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam (D. Nguyen Hong, M.N.T. Huyen, N.T.N. Lan, N.H. Duong, V.V. Nguyen Ngo, D.T. Ngoc, T Nguyen); Pediatric Hospital Nhi Dong 1, Ho Chi Minh City (K.T. Huu); Pediatric Hospital Nhi Dong 2, Ho Chi Minh City (V.D. Chau); Institut Pasteur, Phnom Penh, Cambodia (O. Marcy); INSERM U 1058, Montpellier, France (P. Van de Perre, S. Godreuil); Université Montpellier 1, Montpellier (P. Van de Perre, S. Godreuil); CHU Montpellier, Montpellier (P. Van de Perre, S. Godreuil); and MIVEGEC, Universités Montpellier 1 et 2, Montpellier (A.-L. Bañuls).

DOI: http://dx.doi.org/10.3201/eid1907.130025
Bulelia extructa Periprosthetic Hip Joint Infection, United States

To the Editor: Bulelia extructa is an obligately anaerobic, nonmotile, non–spore-forming gram-positive bacillus first described in 2000 by Downes et al. (1), after having isolated a bacterium from the oral cavity of persons with periodontitis and den-toalveolar abscesses that did not correspond to any known species. After phenotypic and genetic characterization, the investigators proposed a new genus, Bulelia, and the species B. extructa. Since then, additional reports have associated the organism with oral infections, specifically periodontal disease (2–5). While B. extructa’s association with human periodontal disease is well documented, the bacterium has so far not been implicated in other pathogenic processes. We report here a case of a total hip arthroplasty infection caused by B. extructa in an immunocompetent patient.

In November 2010, an 82-year-old man with a non-cemented right total hip arthroplasty—specifically with extension, flexion, abduction, and adduction. Results of the patient’s blood work were notable for normocytic anemia (hemoglobin 10.6 g/dL), thrombocytosis (459 × 10^9/L), elevated erythrocyte sedimentation rate (101 mm/h), and elevated C-reactive protein (88.7 mg/L). Leukocyte count was within normal limits (9.6 × 10^9 cells/L). An ultrasound examination of the right hip joint showed extensive synovitis and a large, 4.3 × 5.0 × 5.1-cm vascular mass extending anteriorly from the joint space. Aspiration of the joint space yielded 1 mL of blood-stained fluid with 111,595 cells/µL (95% neutrophils, 5% monocytes/macrophages). Anaerobic bacterial culture grew a gram-positive bacillus identified as B. extructa by partial 16S rRNA sequencing. DNA was prepared for PCR amplification by using PrepMan Ultra (Applied Biosystems, Foster City, CA, USA) and amplified and bidirectionally sequenced by using primers 5′-TGGAGAGTTTGATCTTGCTCAG-3′ and 5′-TACGGGGCTTGGCAC-3′. The generated 484-bp sequence differed by 2 bp from 483 bp of available sequence from B. extructa GenBank accession no. AF220064. The isolate was susceptible to penicillin, clindamycin, and metronidazole by using E-test.

The patient underwent total hip arthroplasty resection. Intraoperatively, purulence was noted upon entering the hip joint. Histopathologic examination of removed tissue revealed acute inflammation. Five hip tissue specimens were obtained for culture; 3 specimens yielded B. extructa. Six weeks of intravenous ceftriaxone treatment was prescribed, and the patient was instructed to revisit a dentist for a full dental examination. Before seeking treatment for this episode, he reported that he was seeing a dentist on a regular basis and denied any recent dental surgery or infections.

The patient was seen in a follow-up visit 2 months after reimplantation surgery; at that time, he reported minimal pain and had begun to bear weight on the affected side. There was no evidence for infection recurrence.

Periprosthetic joint infections are a major complication after joint replacement. The number of procedures for total hip and knee replacements has

References

1. Azzopardi P, Bennett CM, Graham SM, Duke T. Bacille Calmette-Guerin vaccine-related disease in HIV-infected children: a systematic review. Int J Tuberc Lung Dis. 2009;13:1331–44.
2. Hesseling AC, Caldwell J, Cotton MF, Eley BS, Jaspal HB, Jennings K, et al. BCG vaccination in South African HIV-exposed infants—risks and benefits. S Afr Med J. 2009;99:88–91.
3. Hesseling AC, Rabie H, Marais BJ, Manders M, Lips M, Schaaf HS, et al. Bacille Calmette-Guerin vaccine–induced disease in HIV-infected and HIV-uninfected children. Clin Infect Dis. 2006;42:548–58. http://dx.doi.org/10.1086/499953
4. Hesseling AC, Schaaf HS, Hanekom WA, Beyers N, Cotton MF, Gie RP, et al. Danish bacille Calmette-Guerin vaccine–induced disease in human immunodeficiency virus–infected children. Clin Infect Dis. 2003;37:1226–33. http://dx.doi.org/10.1086/376298
5. Mironova S, Pimkina E, Kontsevaya I, Nikolayevskyy V, Balabanova Y, Skenders G, et al. Performance of the GenoType MTBDRPlus assay in routine settings: a multicenter study. Eur J Clin Microbiol Infect Dis. 2012;31:1381–7. http://dx.doi.org/10.1007/s10096-011-1453-1
6. Ritz N, Tebruegge M, Connell TG, Sievers A, Robins-Browne R, Curtis N. Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. Antimicrob Agents Chemother. 2009;53:316–8. http://dx.doi.org/10.1128/AAC.01302-08
7. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, et al. Detection of rifampicin resistance mutations in Mycobacterium tuberculosis. Lancet. 1993;341:647–50. http://dx.doi.org/10.1016/0140-6736(93)90417-F
8. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359:2233–44. http://dx.doi.org/10.1056/NEJMoa0800971
9. Wayne LG. Microbiology of tubercle bacilli. Am Rev Respir Dis. 1982;125:31–41.

Address for correspondence: Sylvain Godreuil, Centre Hospitalo–Universitaire, Hôpital Arnaud Villeneuve—Laboratoire de Bactériologie, 371 Avenue du Doyen Gaston Giraud, Montpellier cedex 5 34295, France; email: godreuil@yahoo.fr